#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Brian Eater Email
Executive Director . QED Therapeutics
Palo Alto, CA
LocationPrimary Email
How to contact Brian Eater
Join and see Brian's contact info for free!Current Roles
Employees:
44Revenue:
$3.4MAbout
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.QED Therapeutics Address
421 Kipling St.Palo Alto, CA
United States